Synopsis: In this episode of the Biotech2050 podcast, Jak Knowles, co-founder of Affini-T Therapeutics, shares valuable insights into the challenges faced by bootstrapped biotech companies and the significance of venture capital in the industry. Knowles discusses the importance of finding key partners and securing intellectual property early on, shedding light on the capital-intensive nature of drug development. Furthermore, he highlights the value of experienced investors and the impact of their investment source, emphasizing the advantage of being one of the first investments out of a fund. Knowles also provides an update on Affini-T Therapeutics' focus on developing therapies for solid tumors, offering a glimpse into their innovative approach using cell therapy and synthetic biology to address the challenges of the tumor microenvironment. His journey and expertise in navigating the intricacies of fundraising and company-building make this episode essential listening for entrepreneurs in the biotech industry, providing practical lessons and strategic insights for overcoming funding obstacles and driving success in the competitive landscape of biotechnology.,In this episode of the Biotech2050 podcast, Jak Knowles, the co-founder of Affini-T Therapeutics, offers valuable perspectives on the challenges encountered by bootstrapped biotech companies and the pivotal role of venture capital in the industry. Knowles emphasizes the significance of early intellectual property acquisition and strategic partnerships as critical factors in the capital-intensive arena of drug development. Furthermore, he underscores the importance of securing investment from experienced sources and elaborates on the benefits of being an early investment in a fund. Knowles also provides an update on Affini-T Therapeutics' focus on developing innovative therapies for solid tumors, showcasing the company's pioneering approach involving cell therapy and synthetic biology to address the complexities of the tumor microenvironment. With his wealth of experience and expertise, Knowles offers essential insights for biotech entrepreneurs, providing actionable strategies and valuable lessons for navigating the funding landscape and achieving success in the competitive biotechnology sector. Biography: Jak Knowles, MD, is Co-Founder, President and Chief Executive Officer of Affini-T Therapeutics. He has more than two decades of R&D, management, and entrepreneurial experience in the life science industry. Prior to launching Affini-T, Jak served as Co-founder and Chief Business Officer for Metagenomi, a next-generation gene editing company based in Berkeley, California. Jak was previously Head of Pharma Venture Investments for Leaps by Bayer, where he helped lead Metagenomi’s initial seed financing and early strategy serving on Metagenomi’s Board of Directors. Before joining Bayer, Jak served as Chief Executive Officer of CytoSen Therapeutics, where he developed Natural Killer immune cell therapies for oncology indications. In 2016, Jak co-founded and launched Exonics Therapeutics, a CRISPR gene-editing company, serving as President and interim-Chief Executive Officer. Jak previously served on the Board of Directors for Century Therapeutics, Exonics Therapeutics, Metagenomi Technologies, Triumvira Immunologics, and Pyxis Oncology. Jak earned his MD from Stanford University where he graduated with honors in biomedical research, and an undergraduate degree in biology from Binghamton University